跳到正文
原文
PharmaTimes· John Pinching·· 2026-10-19精选AI 评分77

Libtayo(cemiplimab)给药间隔调整获CHMP正面意见

Libtayo dosing backed by CHMP

AI 导读

CHMP就Libtayo(cemiplimab)全部获批适应症推荐批准替代给药方案:初始12周按350 mg每三周一次,之后可改为700 mg每六周一次;若耐受良好,350 mg剂量的输注时间可缩短至15-30分钟。该建议基于药代动力学与药效学建模模拟数据并结合临床安全性与疗效数据,欧洲委员会预计未来数月作出最终决定。

推荐理由

原文明确给出CHMP对Libtayo全部适应症的给药间隔与输注时长调整意见,可作为欧洲监管决策前的关键参考。

正文 · 原文

Regimen update recommended across all indications

The CHMP has issued a positive opinion recommending approval of an alternative dosing schedule for Libtayo (cemiplimab) across all approved indications.

The opinion supports reducing dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. It also recommends an optional reduction of infusion time for the 350 mg dose to 15 to 30 minutes, provided the first dose over 30 minutes was well tolerated.

A spokesperson for Regeneron said: “The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications.”

They added: “The positive CHMP opinion is supported by comprehensive pharmacokinetic and pharmacodynamic modeling and simulation data, integrated with clinical safety and efficacy data from Libtayo’s clinical development program.”

The recommendation supports a higher-dose 700 mg infusion every six weeks following an initial 12-week regimen of 350 mg every three weeks.

It also allows a shorter infusion option for patients continuing on the 350 mg schedule. The European Commission is expected to make a final decision in the coming months, which would enable the updated regimen to be applied across all six approved indications.

The 700 mg six-week option is already approved in the US for use after 12 weeks as an adjuvant treatment for adults with cutaneous squamous cell carcinoma at high risk of recurrence. Across other indications, the existing 350 mg three-week regimen remains in place.

Libtayo is a fully human monoclonal antibody targeting PD-1 and has been approved in more than 30 countries for certain adult patients with advanced BCC, CSCC, NSCLC and cervical cancer.

It is also being investigated in trials as a monotherapy and in combination approaches for other solid tumours, although these potential uses remain investigational and unapproved.

来源:PharmaTimes · pharmatimes.com